“Premji Invest has been an early supporter of Bicara from the beginning, having participated in both our Series A and recent Series B financing. With their support, Bicara is moving forward with urgency towards delivering potential new treatment options to patients struggling with head and neck cancers.”
Claire Mazumdar
CEO, Bicara Therapeutics Inc.
Perspectives
Perspectives
Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
June 1, 2024
Bicara Therapeutics